An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1

An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1

Abstract. Background:. Single-tablet regimen (STR) provides a convenient once-daily regimen for the prevention of human immunodeficiency virus (HIV) infection. Here, we investigated the safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as a three-d...

Full description

Bibliographic Details
Main Authors: An Liu, Ruolei Xin, Hongwei Zhang, Lili Dai, Ruojun (Esther) Wu, Xi Wang, Aixin Li, Wei Hua, Jianwei Li, Ying Shao, Yue Gao, Zhangli Wang, Jiangzhu Ye, Gulimila A bu dou re xi ti, Zaicun Li, Lijun Sun, Yanjie Yin
Format: Article
Language:English
Published: Wolters Kluwer 2022-11-01
Series:Chinese Medical Journal
Online Access:http://journals.lww.com/10.1097/CM9.0000000000002494

Internet

http://journals.lww.com/10.1097/CM9.0000000000002494

Similar Items